VESTAL POINT CAPITAL LP
Q4 2025 Form 13-F
NEW YORK, DELAWARE
CIK 0001974915
· CRD 325894
· SEC-registered investment adviser
$2.9B Reported Value Total
VESTAL POINT CAPITAL, LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $5,469,117,378, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $2.8B gross asset value
Hedge Fund: $2.8B
Source: Form ADV filed 2026-03-31
Reported value
$2.9B
Quarter over quarter
+24.2%
Holdings
75
Top-10 concentration
50.2%
Key People
Form ADV owners & control persons
Ryan Christopher Wilder
MANAGING PARTNER AND CHIEF INVESTMENT OFFICER
Ilko Latchezarov Menkov
PARTNER, COO AND CCO
Benjamin German Carroll
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $2.9B |
| Positions | 75 |
| Change in reported value | +32.8% |
| New positions | 24 |
| Exited positions | 29 |
| Position turnover | 51.0% |
| Top-10 concentration | 50.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
68 | $4.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
90 | $3.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
75 | $2.9B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
80 | $2.2B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
72 | $1.9B |
|
Q1 2025 13F
Filed May 15, 2025
|
63 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
73 | $1.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
67 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
60 | $1.3B |
|
Q1 2024 13F
Filed May 14, 2024
|
58 | $1.2B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
48 | $944.0M |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ABVX Abivax SA | $256.2M | 8.71% |
| 2 | QQQ P Invesco QQQ Trust Series 1 | $215.0M | 7.31% |
| 3 | ACLX Arcellx Inc | $190.7M | 6.48% |
| 4 | TERN Terns Pharmaceuticals Inc | $181.8M | 6.18% |
| 5 | BMRN BioMarin Pharmaceutical Inc | $178.3M | 6.06% |
| 6 | GMED Globus Medical Inc | $111.3M | 3.78% |
| 7 | NRIX Nurix Therapeutics Inc | $89.0M | 3.02% |
| 8 | ALC Alcon AG | $87.1M | 2.96% |
| 9 | DXCM Dexcom Inc | $84.6M | 2.88% |
| 10 | MRK Merck & Co Inc | $81.6M | 2.77% |
| 11 | TSHA Taysha Gene Therapies Inc | $75.6M | 2.57% |
| 12 | ABT Abbott Laboratories | $75.2M | 2.56% |
| 13 | IMTX Immatics NV | $64.3M | 2.19% |
| 14 | TYRA Tyra Biosciences Inc | $63.8M | 2.17% |
| 15 | BCAX Bicara Therapeutics Inc | $60.2M | 2.05% |
| 16 | ARWR Arrowhead Pharmaceuticals Inc | $59.8M | 2.03% |
| 17 | ELVN Enliven Therapeutics Inc | $59.0M | 2.01% |
| 18 | IRON Disc Medicine Inc | $58.4M | 1.98% |
| 19 | JAZZ Jazz Pharmaceuticals PLC | $49.3M | 1.68% |
| 20 | DAWN Day One Biopharmaceuticals Inc | $48.5M | 1.65% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.